### ü´Ä Cardiomyopathy: Provokable Obstruction in Hypertrophic Cardiomyopathy

#### ‚úÖ True Statements
1. **Transthoracic echocardiography (TTE)** is the first-line test in diagnosing **hypertrophic cardiomyopathy (HCM)**.
2. TTE demonstrates the degree and location of **left ventricular (LV) hypertrophy**, which is defined as **‚â•15 mm in any LV region** or **‚â•13 mm in a person with a first-degree relative with HCM or genotype-positive status**.
3. TTE can quantify the **left ventricular outflow tract (LVOT) gradient**, which differentiates **obstructive** from **nonobstructive HCM**.
4. In patients with a **resting LVOT gradient <50 mm Hg**, obstruction should be provoked using the **Valsalva maneuver** or **exercise**.
5. **Stress echocardiography** is indicated in patients with exertional symptoms and a resting LVOT gradient <50 mm Hg to determine whether obstruction is provokable.
6. **Cardiac catheterization** may be used in HCM to measure gradients, assess for **coronary artery disease (CAD)** or **myocardial bridging**, and evaluate **septal perforating arteries** if **alcohol septal ablation** is considered.
7. **Cardiac positron emission tomography (PET)** imaging cannot be used to measure intracardiac pressure gradients.
8. **Transesophageal echocardiography (TEE)** may be used in HCM to clarify anatomy when **TTE is suboptimal** or to plan **septal reduction therapy** in patients with **refractory symptomatic LVOT obstruction**.

#### üí¨ Extra
1. TTE is both diagnostic and useful for physiologic assessment in HCM.
2. These hypertrophy thresholds guide diagnosis and genetic screening decisions.
3. Differentiating obstructive from nonobstructive HCM guides symptom-directed therapy.
4. Provoking obstruction helps identify symptomatic patients who would benefit from therapy such as Œ≤-blockers.
5. The patient in the vignette had symptoms suggestive of obstruction but a resting gradient <30 mm Hg.
6. Cardiac catheterization is reserved for additional structural or procedural evaluation, not initial assessment of obstruction.
7. Cardiac PET is useful for ischemia evaluation but not hemodynamic measurements.
8. TEE is typically used in procedural planning or when transthoracic imaging is limited.

#### üìá Tags
#Cardiology #HypertrophicCardiomyopathy #Echocardiography #StressEcho #LVOTObstruction #TEE #CardiacPET #CardiacCath

#### üìö Reference
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2020;142:e558-e631. PMID: 33215931 doi:10.1161/CIR.0000000000000937

#### üÜî Question ID
CVMCQ24076

#### üïí Last Updated
January 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Myocardial Disease, Hypertrophic Cardiomyopathy

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Twelve-lead electrocardiogram (ECG)** reveals abnormal findings in **75% to 95%** of patients with **hypertrophic cardiomyopathy (HCM)**.
2. Common ECG abnormalities in HCM include **increased QRS voltage**, **left atrial enlargement**, **left ventricular conduction abnormalities**, **pathologic Q waves**, and **significant repolarization abnormalities**.
3. **Doppler echocardiography** is the modality of choice for **quantifying the LVOT gradient** in HCM.
4. In patients with HCM and **resting LVOT gradient <50 mm Hg**, **echocardiography with provocative maneuvers** such as **Valsalva or exercise** is recommended to establish obstruction.
5. **Cardiac magnetic resonance (CMR)** imaging is indicated to clarify the diagnosis of HCM when **echocardiographic findings are inconclusive**.
6. Initial evaluation of HCM should include **24- to 48-hour ambulatory ECG monitoring** to detect **arrhythmias**.
7. The presence of **nonsustained ventricular tachycardia (NSVT)** on ambulatory monitoring indicates a **higher risk for sudden cardiac death (SCD)**.
8. **Exercise stress testing** is reasonable in HCM to assess **functional status** and provide **prognostic information**.
9. **Cardiac magnetic resonance (CMR)** imaging with **gadolinium contrast** may help differentiate HCM from **hypertensive heart disease** and **athlete‚Äôs heart**.

#### üí¨ Extra
1. Most patients with HCM will have some ECG abnormalities on screening.
2. These findings reflect electrical and structural remodeling in HCM.
3. Doppler measurement allows dynamic assessment of flow gradient across the LVOT.
4. Provocation testing improves detection of latent dynamic obstruction.
5. CMR is a complementary tool when echocardiography is nondiagnostic.
6. Ambulatory monitoring is essential for arrhythmic risk stratification in HCM.
7. NSVT is a known predictor for sudden cardiac events in HCM.
8. Exercise capacity can help guide both prognosis and lifestyle recommendations.
9. Gadolinium-enhanced CMR can detect patterns of fibrosis and wall thickness distribution useful for distinguishing HCM from other conditions.

#### üè∑Ô∏è Tags
#HypertrophicCardiomyopathy #LVOTGradient #CMR #AmbulatoryECG #SuddenCardiacDeath #AthletesHeart #Valsalva #StressTest #DopplerEcho

---

### üì∏ Supplemental Figures

**ECG in a Patient With Apical Hypertrophic Cardiomyopathy**  
<img src="ECG in a Patient With Apical Hypertrophic Cardiomyopathy.jpg" alt="ECG showing increased QRS voltage and repolarization abnormalities in V2-V5" width="600"/>

**Echocardiographic Features of Hypertrophic Cardiomyopathy**  
<img src="Echocardiographic Features of Hypertrophic Cardiomyopathy.jpg" alt="Panels A-D showing asymmetrical septal hypertrophy, SAM of mitral leaflet, color Doppler flow, and spectral Doppler profile" width="600"/>

---

### üéûÔ∏è Supplemental Video

**Hypertrophic Cardiomyopathy ‚Äì Bisferiens Pulse and Systolic Murmur**  
<video src="Hypertrophic_Cardiomyopathy.mp4" controls width="600"></video>  
*Used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine.*  
[Source](https://gordoncenter.miami.edu)

---

### üßæ Supplemental Tables

#### Physical Examination Findings of Dynamic Left Ventricular Outflow Tract Obstruction Versus Fixed Valvular Aortic Stenosis

<table border="1" cellspacing="0" cellpadding="6">
<thead>
<tr>
<th>Finding or Maneuver</th>
<th>Hypertrophic Cardiomyopathy With Dynamic LVOT Obstruction</th>
<th>Valvular Aortic Stenosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic of murmur</td>
<td>Ejection-quality murmur usually best heard at left lower sternal border; generally does not radiate to the carotid arteries</td>
<td>Ejection-quality murmur usually best heard at right second intercostal space with radiation to the carotid arteries</td>
</tr>
<tr>
<td>Carotid impulse</td>
<td>Brisk upstroke; may have two impulses for each ejection (bifid)</td>
<td>Upstroke is often diminished and delayed (parvus et tardus)</td>
</tr>
<tr>
<td>Valsalva maneuver</td>
<td>Increase in intensity of murmur during strain phase (LR+ = 14)</td>
<td>No change or diminished murmur intensity during strain phase</td>
</tr>
<tr>
<td>Position</td>
<td>Increase in intensity of murmur with standing from squat or seated position (LR+ = 6.0); decrease in murmur with elevation of legs when supine (LR+ = 7.6)</td>
<td>No significant change in intensity of murmur with position</td>
</tr>
<tr>
<td>Peripheral pulse after PVC</td>
<td>No change or decrease in intensity of pulse</td>
<td>Increase in intensity of pulse</td>
</tr>
</tbody>
</table>

<small>LR+ = positive likelihood ratio; LVOT = left ventricular outflow tract; PVC = premature ventricular contraction.</small>

---

#### Conditions With Increased Left Ventricular Wall Thickness

<table border="1" cellspacing="0" cellpadding="6">
<thead>
<tr>
<th>Condition</th>
<th>Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Elevated blood pressure</td>
</tr>
<tr>
<td>Athlete heart</td>
<td>No hypertension; normal or supranormal exercise capacity</td>
</tr>
<tr>
<td>Amyloidosis</td>
<td>Heart failure, low voltage on ECG, possible neuropathy and/or nephropathy; usually older patients</td>
</tr>
<tr>
<td>Fabry disease</td>
<td>Male predominance (X-linked), neuropathic pain, kidney dysfunction, telangiectasias, angiokeratomas; typically young patients</td>
</tr>
<tr>
<td>Friedreich ataxia</td>
<td>Ataxia, scoliosis, pes cavus (high foot arches), visual and hearing impairment</td>
</tr>
</tbody>
</table>